While some countries and pharmaceutical companies are efficiently conducting mass vaccination campaigns in the media, others are doing it in reality, albeit less successfully. US company Pfizer expects to sell $15 billion in coronavirus vaccine doses this year. In total, the drugmaker estimates that it will earn from $59.4 billion to $61.4 billion by the end of this year.
The pharmaceutical firm has big plans, as its coronavirus vaccine developed jointly with German company BioNTech has proved the most effective to date. The number of countries wishing to purchase Pfizer's vaccine doses is growing. Moreover, there are even those countries among them that seemed to have developed their own vaccine and have implemented successful vaccination programmes.
Besides, the vaccine's high price is not a deterrent to those who are interested in the drug. Its cost is several times higher than that of the main competitors. The purchase price of Pfizer’s two-dose vaccine amounts to $19.5 per shot. AstraZeneca is planning to sell its vaccine at less than $4 per dose, and Johnson & Johnson's drug is priced at roughly $10 per dose. Such strong demand forced the company to increase its production plan. Initially, Pfizer was going to produce 1.3 billion doses of its coronavirus vaccine in 2021. Now the firm is preparing to deliver up to 2 billion doses.
So far, Pfizer and BioNTech have agreed to deliver 836 million doses of vaccine, including 300 million for the European Union and 200 million for the United States.
